Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Lymphohistiocytosis, Hemophagocytic 1

Interventions

pembrolizumab 37Carboplatin 31Cisplatin 30Paclitaxel 23Nivolumab 21Pemetrexed 21Dexamethasone 18Gemcitabine 18Ipilimumab 15Docetaxel 13Fluorouracil 13Capecitabine 12Rituximab 12Cyclophosphamide 10Cytarabine 10Trastuzumab 9atezolizumab 9daratumumab 9olaparib 9130-nm albumin-bound paclitaxel 8Lenalidomide 8Prednisone 8durvalumab 8trastuzumab deruxtecan 8Bevacizumab 7Bortezomib 7Fulvestrant 7Oxaliplatin 7Vinorelbine 7cabozantinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Has announcements × Emapalumab × Clear all
NCT01818492 2023-02-21

Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis

Swedish Orphan Biovitrum

Phase 2/3 Completed
45 enrolled 20 charts 1 FDA
Myeloid

Lymphohistiocytosis, Hemophagocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡